Cancer Research Cancer Epigenetics  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 7882-7886, December 15, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, A. H.
Right arrow Articles by Luqmani, Y. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, A. H.
Right arrow Articles by Luqmani, Y. A.

Interaction of Vasopressin and Oxytocin with Human Breast Carcinoma Cells

A. H. Taylor, V. T. Y. Ang, J. S. Jenkins, J. J. Silverlight, R. C. Coombes and Y. A. Luqmani1

Divisions of Biochemical Medicine [A. H. T., V. T. Y. A., J. S. J., J. J. S.] and Medical Oncology [R. C. C., Y. A. L.], and Department of Cellular and Molecular Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, England

The arginine vasopressin and oxytocin content of normal and cancerous human breast tissue were measured using radioimmunoassay. Both peptides were present in amounts greater than that found in the circulation, but no difference between normal and malignant tissues was found. Binding of [3H]oxytocin and [3H]vasopressin were characterized in human breast carcinoma cells (MCF7 cells). Binding of both hormones to MCF7 cells was specific and saturable, the vasopressin receptor found to be of the V1 subtype. Scatchard analyses of the data were linear, indicating a single high affinity, low capacity binding site for each hormone (vasopressin: KD = 47.4 ± 1.6 nmol/liter, Bmax = 27.300 ± 6,500 sites/cell; oxytocin: KD = 51.3 ± 0.4 nmol/liter, Bmax = 87,000 ± 4,000 sites/cell). The effects of vasopressin and oxytocin on the growth of MCF7 cells were assessed using protein accumulation and cell numbers. Vasopressin at 10–1000 pmol/liter was mitogenic for MCF7 cells, but higher doses (10 nmol/liter) were growth inhibitory. Oxytocin was also mitogenic for MCF7 cells but to a lesser extent than vasopressin. In conclusion, we suggest that vasopressin and possibly oxytocin may be important modulators of the growth of some human breast carcinomas.

1 To whom requests for reprints should be addressed.

Received 4/ 9/90. Accepted 7/13/90.




This article has been cited by other articles:


Home page
Biol. Reprod.Home page
K. Ndiaye, D. H. Poole, and J. L. Pate
Expression and Regulation of Functional Oxytocin Receptors in Bovine T Lymphocytes
Biol Reprod, April 1, 2008; 78(4): 786 - 793.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
V. Lollivier, P.-G. Marnet, S. Delpal, D. Rainteau, C. Achard, A. Rabot, and M. Ollivier-Bousquet
Oxytocin stimulates secretory processes in lactating rabbit mammary epithelial cells
J. Physiol., January 1, 2006; 570(1): 125 - 140.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Pequeux, C. Breton, J.-C. Hendrick, M.-T. Hagelstein, H. Martens, R. Winkler, V. Geenen, and J.-J. Legros
Oxytocin Synthesis and Oxytocin Receptor Expression by Cell Lines of Human Small Cell Carcinoma of the Lung Stimulate Tumor Growth through Autocrine/Paracrine Signaling
Cancer Res., August 15, 2002; 62(16): 4623 - 4629.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Bussolati and P. Cassoni
Editorial: The Oxytocin/Oxytocin Receptor System--Expect the Unexpected
Endocrinology, April 1, 2001; 142(4): 1377 - 1379.
[Full Text]


Home page
Physiol. Rev.Home page
G. Gimpl and F. Fahrenholz
The Oxytocin Receptor System: Structure, Function, and Regulation
Physiol Rev, April 1, 2001; 81(2): 629 - 683.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. F. Novak, M. B. Judkins, M. I. Chernin, P. Cassoni, G. Bussolati, J. A. Nitche, and S. K. Nishimoto
A Plasmin-derived Hexapeptide from the Carboxyl End of Osteocalcin Counteracts Oxytocin-mediated Growth of Inhibition of Osteosarcoma Cells
Cancer Res., July 1, 2000; 60(13): 3470 - 3476.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
J. A. Copland, Y.-J. Jeng, Z. Strakova, K. L. Ives, M. R. Hellmich, and M. S. Soloff
Demonstration of Functional Oxytocin Receptors in Human Breast Hs578T Cells and Their Up-Regulation through a Protein Kinase C-Dependent Pathway
Endocrinology, May 1, 1999; 140(5): 2258 - 2267.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
T. L. Bale and D. M. Dorsa
Cloning, Novel Promoter Sequence, and Estrogen Regulation of a Rat Oxytocin Receptor Gene
Endocrinology, March 1, 1997; 138(3): 1151 - 1158.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.